Restart Life Sciences Corp.

OTC: NMLSF · Healthcare · Biotechnology

Canadian filerHQ Vancouver, BCCIK 0001689231Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 51

v0.1 · 5/100 weight · pillars only

↑ listing tenure, Piotroski F · ↓ Altman-Z, market scale

Methodology →

Revenue TTM

$337.5k

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

—

Employees

—

as of 2026-08-25

Market cap

$2.3M

as of 2026-08-25

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

No filed financials — private or non-XBRL filer.

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Restart Life Sciences Corp.’s financial profile?

Restart Life Sciences Corp. has no structured financials on file — private or non-XBRL filer.

Peers · Healthcare

Clearmind Medicine Inc.——Endovia Health Sciences, Inc.——Artelo Biosciences, Inc.——1933 Industries Inc.——Shuttle Pharmaceuticals Holdings, Inc.——Algernon Pharmaceuticals Inc.——

Key facts

CEOSteve Loutskou

SectorHealthcare

IndustryBiotechnology

HeadquartersVancouver, BC

ExchangeOTC: NMLSF

Employees—

IPO date2011-10-19

Latest filings

No filings loaded.

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.